Trademarkia Logo

Australia

AU$
XERISOL
Protected: Registered/protected

Last updated on 26 Oct 2021

Owner Info

Xeris Pharmaceuticals, Inc.

180 N LaSalle Street, Suite 1810

Chicago IL 60601, UNITED STATES OF AMERICA

Serial Number

2201871 filed on 3 Jun 2021

Correspondent

Tracy-Gene G. Durkin Sterne, Kessler, Goldstein & Fox P.L.L.C.

1100 New York Avenue, NW,

Washington DC 20005,

UNITED STATES OF AMERICA

XERISOL

Classification Information


Class [005]
Pharmaceutical preparations for the treatment of diseases and conditions, namely, alimentary tract, metabolic, oncologic, autoimmune, and nervous syst Read More

Class [042]
Pharmaceutical research and development; pharmaceutical drug formulation and development services; providing information on drug technology platforms Read More

Mark Details


Serial Number

2201871

Registered On

3 Jun 2021

Renewal On

3 Jun 2031

Mark Type

WORD

Priority Claim (Convention Details)


Date

4 Dec 2020

Mark Type

US

Legal History


Show more

Status DateAction Taken
26th Oct 2021International Registration in Australia Protected correspondence sent
25th Oct 2021IP Right Registration Published
25th Oct 2021Status change to Registered/Protected
17th Aug 2021Application Accepted correspondence sent
16th Aug 2021IP Right has been Examined
16th Aug 2021IP Right Acceptance Published
16th Aug 2021Status change to Accepted
13th Aug 2021Awaiting examination
13th Aug 2021Examination expedited
12th Aug 2021IP Right Filed Published